Update on the activity of Ligand and its partners:
- SP continues to be volatile (currently US$143.96), although Yahoo Finance have their 5 year beta at 1.03 which suggests it carries a small risk premium vs the volatility of the NASDAQ
- partner Gloria Biosciences received approval for its Hodgkin's Lymphoma treatment in China (30 Aug)
- CRDC (China Resources Double Crane Pharmaceuticals) entered into an agreement with Ligand to develop an oral treatment for Cvd19 (21 Oct)
- partner Sermonix successfully raised funds to continue clinical testing for lasofoxifene for the treatment of breast cancers (16 Nov)
- partner Gilead expects Remdesivir (aka Veklury) to continue to be effective with the Omicron variant of Cvd19 (1 Dec)
- US FDA accepts priority review for partner Merck's pneumococcal vaccine Vaxneuvance (1 Dec)
- partner Amgen to present clinic trial findings relating to its hematology pipeline (6 Dec)
- partner Jazz Pharmaceuticals announced positive stage 2/3 clinical trials for its drug Rylaze, used for the treatment of complications pertaining to asparaginase treatment of lymphoblastic and lymphoblastic lymphoma (12 Dec)
Latest investor presentation (19 Nov) shows 130+ partners on p5 and a healthy pipeline of circa 300 drugs in various stages of development.
Reply With Quote
Bookmarks